<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463121</url>
  </required_header>
  <id_info>
    <org_study_id>BBM MOD PV CS-06</org_study_id>
    <nct_id>NCT04463121</nct_id>
  </id_info>
  <brief_title>Preload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06)</brief_title>
  <acronym>CS-06</acronym>
  <official_title>Pressure-Volume (PV) Measurements for Evaluating the Changes in the Ventricular Preload and Autonomic Nervous System Using BackBeat Medical Cardiac Neuromodulation Therapy (CNT) Signals in an Acute Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BackBeat Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CD Leycom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BackBeat Medical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will evaluate the effect of RV pacing lead position on cardiac function
      and the modulation of the autonomic nervous system with Cardiac Neuromodulation Therapy (CNT)
      pacing signals. The study will be performed acutely prior to a pacemaker implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects indicated for a dual chamber pacemaker implant or replacement who are not 100%
      dependent on right ventricular pacing may be eligible to participate in the study.

      This investigation will evaluate the effect of RV pacing lead position on cardiac function
      and the modulation of the autonomic nervous system using Cardiac Neuromodulation Therapy
      (CNT) pacing signals at different positions of the RV pacing lead.

      A standard conductance catheter will be introduced through the femoral artery and advanced
      into the left ventricle to measure cardiac volumes and pressure.

      Arterial blood pressure will be measured either from the femoral artery sheath through which
      the conductance catheter is introduced, or from a radial arterial line.

      The Moderato® IPG will be used to generate Cardiac Neuromodulation Therapy (CNT) signals and
      deliver them to the patient through the cable and leads. A range of CNT signal parameters
      will be used to assess the effect on sympathetic activity at different positions of the RV
      pacing lead. Ventricular pressure and volume readings from the conductance catheter and
      arterial pressure readings will be recorded and analyzed to assess the effect of CNT signals
      on cardiac function, sympathetic activity and blood pressure.

      The effects of CNT signal over a range of parameter settings will be studied for the
      different RV lead positions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 3, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of the Moderato CNT pacing signals on cardiac function</measure>
    <time_frame>approximately one hour</time_frame>
    <description>Left ventricular pressure (mmHg) and Volume (ml) will be obtained by a multisensor catheter which provides real-time, beat-to-beat intra-ventricular measurement of cardiac function and performance. Data will be used to generate Pressure-Volume Loops, an aknowledged way to describe hemodynamic changes. CNT signals (alternating short and long atrioventicular sequences 40-150 ms) will be delivered at the same by right ventricular pacemaker leads temporarely connected to the Moderato device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of CNT pacing signals on blood pressure</measure>
    <time_frame>aproximately onr hour</time_frame>
    <description>Blood pressure (mmHg) will be obtained in parallel with a Millar catheter from the femoral artery througout the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Bradycardia</condition>
  <condition>Hypertension, Systolic</condition>
  <arm_group>
    <arm_group_label>Acute CNT pacing signals testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.
Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.
A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Moderato IPG's CNT pacing signals</intervention_name>
    <description>Assesment of cardiac function and sympatheric activity will be obtained simultaneously</description>
    <arm_group_label>Acute CNT pacing signals testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CD Leycom Pressure/Volume Combination Catheters</intervention_name>
    <description>Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.</description>
    <arm_group_label>Acute CNT pacing signals testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥ 18 years of age

          2. Subject requires implantation or replacement of a dual chamber pacemaker or requires
             an upgrade from a single chamber to a dual chamber pacemaker

          3. Subject has known Hypertension

          4. Subject is willing and able to comply with the study and procedures.

        Exclusion Criteria:

          1. Subject has symptoms of heart failure, NYHA Class II or greater

          2. Subject has significant (&gt;2+) mitral regurgitation, aortic regurgitation or aortic
             stenosis.

          3. Subject has permanent atrial fibrillation

          4. Subject has atrial fibrillation on the day of the study.

          5. Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy or
             interventricular septal thickness ≥15 mm

          6. Subject is on dialysis

          7. Subject has a history of prior neurological events (stroke or TIA) within the past
             year or a neurological event (stroke or TIA) at any prior time that has resulted in
             residual neurologic deficit.

          8. Subject has a history of autonomic dysfunction

          9. Women who are pregnant or breast-feeding

         10. Subject cannot or is unwilling to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Na Homolce Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuval Mika, PhD</last_name>
    <phone>+18569123155</phone>
    <email>ymika@orchestrabiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Norbert Rosenthal</last_name>
    <phone>+491792482543</phone>
    <email>nrosenthal@orchestrabiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Praha</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, MD, PhD</last_name>
      <phone>+420 257272211</phone>
      <email>Peter.Neuzil@homolka.cz</email>
    </contact>
    <contact_backup>
      <last_name>Libor Dujka, MD</last_name>
      <phone>+420731486352</phone>
      <email>libor.dujka@homolka.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Petr Neuzil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filip Malek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Petru, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milan Chovanec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Libor Dujka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Yang B, Wang Y, Zhang F, Ju W, Chen H, Mika Y, Aviv R, Evans SJ, Burkhoff D, Wang J, Chen M. Rationale and evidence for the development of a durable device-based cardiac neuromodulation therapy for hypertension. J Am Soc Hypertens. 2018 May;12(5):381-391. doi: 10.1016/j.jash.2018.03.004. Epub 2018 Mar 21.</citation>
    <PMID>29628351</PMID>
  </reference>
  <reference>
    <citation>Neuzil P, Merkely B, Erglis A, Marinskis G, de Groot JR, Schmidinger H, Rodriguez Venegas M, Voskuil M, Sturmberger T, Petru J, Jongejan N, Aichinger J, Kamzola G, Aidietis A, Gellér L, Mraz T, Osztheimer I, Mika Y, Evans S, Burkhoff D, Kuck KH; BackBeat Study Investigators. Pacemaker-Mediated Programmable Hypertension Control Therapy. J Am Heart Assoc. 2017 Dec 23;6(12). pii: e006974. doi: 10.1161/JAHA.117.006974.</citation>
    <PMID>29275370</PMID>
  </reference>
  <reference>
    <citation>de Roest GJ, Allaart CP, Kleijn SA, Delnoy PP, Wu L, Hendriks ML, Bronzwaer JG, van Rossum AC, de Cock CC. Prediction of long-term outcome of cardiac resynchronization therapy by acute pressure-volume loop measurements. Eur J Heart Fail. 2013 Mar;15(3):299-307. doi: 10.1093/eurjhf/hfs190. Epub 2012 Nov 25.</citation>
    <PMID>23183349</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

